Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years

Main Article Content

Eric L. Simpson
Johnathan Silverberg
Audrey Nosbaum
Kevin Winthrop
Emma Guttman-Yassky
Karin M. Hoffmeister
Alexander Egeberg
Hernan Valdez
Haiyun Fan
Saleem A. Farooqui
Gary L. Chan
Justine Alderfer
William Romero
Susan Johnson


Abrocitinib, JAK1 inhibitor, moderate-to-severe atopic dermatitis, Long-Term Safety, JADE EXTEND


1. Cibinqo (abrocitinib). Summary of product characteristics. European Medicines Agency; December 17, 2021.

2. Cibinqo (abrocitinib) tablets. Prescribing information. Pfizer Labs; January 2022.

3. Cibinqo (abrocitinib), 100 mg film-coated tablets. Summary of product characteristics. Pfizer Ltd.; September 10, 2021.

4. Simpson EL et al. Am J Clin Dermatol. 2021;22:693-707.

5. Cork MJ et al. Presented at: European Academy of Dermatology and Venereology (EADV) Congress; September 29-October 2, 2021; Berlin, Germany.

Most read articles by the same author(s)

1 2 > >>